These individuals were identified in a cohort of patients subjected to targeted Next-Generation Sequencing of COL4A3, COL4A4, and COL4A5 genes as part of commercial genetic screening panels (nephrotic syndrome, focal segmental glomerulosclerosis (FSGS), and AS) or evaluation of other suspected genetic renal diseases. This evidence concerns the gene COL4A5 and focal segmental glomerulosclerosis.